ICPT Key Stats
|Revenue (Quarterly YoY Growth)||-22.51%|
|EPS Diluted (TTM)||-5.095|
|EPS Diluted (Quarterly YoY Growth)|
|Net Income (TTM)||-86.11M|
|Gross Profit Margin (Quarterly)|
|Profit Margin (Quarterly)||-7828%|
|Dividend Yield (TTM)||0%|
|Payout Ratio (TTM) Pro||Go Pro|
- INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Dec 2
- Analysis Of Intercept Pharmaceutical And OCA's Future Potential Nov 19
- Intercept Pharma 3Q loss jumps on bigger charges Nov 14
- Intercept Pharmaceuticals Enters Oversold Territory (ICPT) Nov 14
- Intercept Pharm (ICPT) Posts Q3 Loss of $1.65/Share Street Insider Nov 14
- INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition Nov 14
- Intercept Pharmaceuticals Reports Third Quarter 2013 Financial Results noodls Nov 14
- INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement Nov 7
- Biotech IPOs: The Exit Challenge As Lockups Expire Oct 30
- 4 Stocks Rising on Unusual Volume Oct 24
ICPT Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). ntercept Pharmaceuticals is up 111.8% over the last year vs S&P 500 Total Return up 30.68%, Rockwell Medical up 83.71%, and KYTHERA Biopharmaceutical up 57.10%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for ICPT
Pro Report PDF for ICPT
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download ICPT Pro Report PDF
Pro Strategies Featuring ICPT
Did ntercept Pharmaceuticals make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Intercept Pharmaceuticals Inc is a development stage, biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver disease utilizing its proprietary bile acid chemistry.